Company news

Helix Biopharma Corp. (TSX:HBP) news

Helix Biopharma Corp. news releases on 6ix. Latest, Sep 28, 2026: Helix BioPharma Strengthens Biotech Leadership and Corporate Governance Through Planned…

Helix Biopharma Corp. (TSX:HBP) news

Press releases & updates

Helix BioPharma Strengthens Biotech Leadership and Corporate Governance Through Planned Board Changes

Helix BioPharma Corp. Appoints Markus Loeffler, MD, MBA, as Chief Medical Officer to Support Next Phase of Clinical Development

Helix Biopharma Corp. Announces Board Composition Changes

Helix BioPharma Corp. Strengthens Executive Leadership to Support U.S. Listing Strategy and Next Phase of Clinical Development

Helix BioPharma : Q3 2026 MD&A | Management’s discussion and analysis of financial condition and results of operations

Helix Biopharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Nine-Month Periods Ended April 30, 2026

Helix BioPharma Corp. Announces Closing of Private Placement of Convertible Debentures

Helix BioPharma Corp. Announces Grant and Cancellation of Stock Options

Helix Biopharma Corp. Announces Strategic Board and Governance Appointments to Support Financing and Nasdaq Uplisting Strategy

Helix BioPharma : Q2 2026 MD&A | Management’s discussion and analysis of financial condition and results of operations

Helix BioPharma : Financial statements, Second Quarter 2026

Helix BioPharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026

Helix BioPharma Corp. Announces Presentation at 16th Annual World ADC London

Helix Biopharma Corp. Extends LEUMUNA Option with metaShape Pharma for Adipose Tissue-Related and Metabolic Diseases

Helix Biopharma Corp. Extends LEUMUNA Option With metaShape Pharma for Adipose Tissue-Related and Metabolic Diseases

Helix BioPharma Corp. Announces Voting Results from its Annual General and Special Meeting

Helix BioPharma Corp. Announces Voting Results From Its Annual General and Special Meeting

Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three-Month Period Ended October 31, 2025

Helix BioPharma Corp. Announces Fiscal 2025 Year-End Results

Helix BioPharma Responds to Market Activity

Helix BioPharma Announces Presentation at Q3 Investor Summit Virtual on 16 September 2025

Helix BioPharma Concludes Review, Will Not Proceed with Proposed Equity Draw-Down Subscription Facility with GEM

Helix BioPharma Concludes Review, Will Not Proceed With Proposed Equity Draw-Down Subscription Facility With GEM

Helix Biopharma Corp. Announces Closing of Private Placement, in Preparation for Institutional Investment and NASDAQ Uplisting

Helix Biopharma Corp. Announces Publication in Frontiers in Oncology on the Effects of L-DOS47 as Monotherapy in NSCLC

Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Nine Month Period Ended April 30, 2025

Helix BioPharma Corp. Announces CFO Appointment to Support Strategic Growth and Upcoming Milestones

Helix BioPharma (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") Secures Pre-IND Candidates LEUMUNA(TM) and GEMCEDA(TM) in Strategic Acquisition from the Laevoroc Group

Helix BioPharma Corp. (HBP.TO) Signs Capital Raising Agreement with Kerentech Consulting Ltd.

Helix BioPharma Corp. Appoints New COO and Communications Director to Accelerate Growth and Deliver on its Mission Against Hard-to-Treat Cancers

Helix BioPharma Corp. Appoints Dr. Thomas Mehrling as Chief Executive Officer to Drive Ambitious Clinical Development Plan

Helix BioPharma Corp. Announces Engagement of Independent Trading Group to Provide Market-Making Services

Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three and Six Month Periods Ended January 31, 2025

Helix BioPharma Corp. Announces Upcoming Poster Presentation at the 20th European Molecular Imaging Meeting in Bilbao, Spain

Helix Biopharma Corp. Expands Leadership Team With World-Class Oncology and Scientific Experts

Helix Biopharma Corp. Expands Leadership Team with World-Class Oncology and Scientific Experts

Helix BioPharma Corp. receives approval for the Extension of Annual General and Special Meeting to Seek Approval of Asset Acquisitions and Proposed Financing

Helix BioPharma Corp. Extends Date of Annual General and Special Meeting to Seek Approval of Asset Acquisitions and Proposed Financing

Helix Biopharma Corp. Announces Closing of Private Placement of Common Shares

Helix BioPharma Corp. Appoints James B. Murphy as Chief Financial Officer

Helix BioPharma Amends Acquisition Agreements to Finalise Share Consideration Ahead of Potential Financing

Helix Biopharma Corp. Enters into Asset Purchase Agreement to Acquire Oral Gemcitabine Chemotherapy Compound

Helix Biopharma Corp. Enters into Asset Purchase Agreement to Acquire Oral Immune Checkpoint Inhibitor and Expand Immune-Oncology Portfolio

Helix Biopharma Corp. Announces Issuance of U.S. Patent

Helix BioPharma Corp. Attends World ADC San Diego

Helix Biopharma Corp. Announces CFO and Corporate Secretary Resignation

Canadian Investment Regulatory Organization Trade Resumption - HBP

Canadian Investment Regulatory Organization Trading Halt - HBP

Helix BioPharma Corp. Reports Voting Results

Helix BioPharma Corp. Announces Fiscal 2024 First Quarter Results